A periodic e-newsletter about the introduction of depo-subQ in Uniject

Introduction Planning Update is a periodic newsletter intended to share information with partners, advisors, and stakeholders of PATH’s Planning for Introduction of depo-subQ provera 104™ in the Uniject™ Injection System (depo-subQ in Uniject) project. Each issue contains updates on research, product registration, and introduction planning, and also provides information about related resources that may be of interest to the project’s global and country stakeholders.

Uniject is a trademark of BD. Depo-Provera and depo-subQ provera 104 are trademarks of Pfizer.

Photo: PATH/Patrick McKern.